Document is current
Any future updates will be listed below
-
Authors
Nomura, Motoo https://orcid.org/0000-0002-5967-0610
Yamaguchi, Toshifumi
Chin, Keisho
Hato, Shinji
Kato, Ken
Baba, Eishi
Matsubara, Hisahiro
Mukaida, Hidenori
Yoshii, Takako
Tsuda, Masahiro
Tsubosa, Yasuhiro
Kitagawa, Yuko
Oze, Isao
Ishikawa, Hideki
Muto, Manabu
-
Funding
Funding for this research was provided by:
Taiho Pharmaceutical (Research funding (sponsored research program))
- License Information
-
More Information
Article History
Received: 5 August 2024
Accepted: 24 September 2024
First Online: 7 October 2024
Disclosure
: Toshifumi Yamaguchi, Keisho Chin, Shinji Hato, Ken Kato, Hidenori Mukaida, Takako Yoshii, Masahiro Tsuda, Yasuhiro Tsubosa, Isao Oze, and Hideki Ishikawa have no conflicts of interest to declare and have no financial or funding support to disclose. Hisahiro Matsubara, Yuko Kitagawa, and Manabu Muto have received research funding from Taiho Pharmaceutical. Motoo Nomura has received honoraria from Bristol-Myers Squibb, MDS, Ono Pharmaceutical. Eishi Baba has received lectures fees from AstraZeneca, BMS, Chugai, Takeda, Gardant Health Japan, Ono, Astellas, Softbank, Daiichi-Sankyo, MSD, Yakult, Eli Lilly, Merk biopharm, Taiho, Tsumura, and Amgen
: All procedures were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1964 and later versions. Informed consent, or a substitute, was obtained from all patients before inclusion in the study.
